Liberty Wealth Management LLC Boosts Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Liberty Wealth Management LLC grew its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 8,083.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,766 shares of the biotechnology company’s stock after buying an additional 12,610 shares during the period. Liberty Wealth Management LLC’s holdings in BioMarin Pharmaceutical were worth $153,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Ameriprise Financial Inc. boosted its position in shares of BioMarin Pharmaceutical by 43.0% during the 1st quarter. Ameriprise Financial Inc. now owns 6,233,335 shares of the biotechnology company’s stock worth $470,682,000 after purchasing an additional 1,873,040 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of BioMarin Pharmaceutical by 29.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,755,379 shares of the biotechnology company’s stock valued at $313,348,000 after purchasing an additional 847,367 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of BioMarin Pharmaceutical by 6.5% in the 2nd quarter. Geode Capital Management LLC now owns 2,308,922 shares of the biotechnology company’s stock valued at $192,379,000 after purchasing an additional 140,877 shares in the last quarter. Palo Alto Investors LP raised its stake in BioMarin Pharmaceutical by 2.4% during the 1st quarter. Palo Alto Investors LP now owns 2,205,750 shares of the biotechnology company’s stock worth $166,556,000 after acquiring an additional 50,700 shares in the last quarter. Finally, Manning & Napier Group LLC raised its stake in BioMarin Pharmaceutical by 1.3% during the 2nd quarter. Manning & Napier Group LLC now owns 1,727,384 shares of the biotechnology company’s stock worth $144,131,000 after acquiring an additional 22,542 shares in the last quarter. 94.44% of the stock is owned by institutional investors and hedge funds.

BMRN opened at $76.82 on Thursday. The company has a quick ratio of 3.71, a current ratio of 5.32 and a debt-to-equity ratio of 0.25. BioMarin Pharmaceutical Inc. has a 52-week low of $71.65 and a 52-week high of $92.57. The company has a 50 day moving average of $78.21 and a two-hundred day moving average of $78.96. The company has a market cap of $14.09 billion, a P/E ratio of 17.91, a P/E/G ratio of 15.81 and a beta of 0.53.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Tuesday, July 27th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.18. BioMarin Pharmaceutical had a net margin of 43.68% and a return on equity of 3.34%. The company had revenue of $501.69 million during the quarter, compared to the consensus estimate of $448.84 million. Research analysts anticipate that BioMarin Pharmaceutical Inc. will post 0.16 earnings per share for the current year.

BMRN has been the topic of several research reports. Royal Bank of Canada reissued a “hold” rating and set a $88.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, September 7th. Zacks Investment Research cut shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating and set a $81.00 target price for the company. in a research report on Tuesday, August 3rd. Jefferies Financial Group began coverage on shares of BioMarin Pharmaceutical in a research report on Thursday, July 29th. They issued a “buy” rating and a $112.00 price objective for the company. Stifel Nicolaus raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price objective for the company from $86.00 to $96.00 in a research report on Thursday, September 9th. Finally, SVB Leerink reissued a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, September 14th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Buy” and an average price target of $101.39.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.

Read More: What is a management fee?

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.